<?xml version="1.0" encoding="UTF-8"?>
<p id="p0190">There were case reports from China, Japan, and Thailand for the effectiveness of the lopinavir-Ritonavir combination in COVID-19 [
 <xref rid="bb0690" ref-type="bibr">138</xref>]. However, the recent clinical trial reported no benefit of the lopinavir-ritonavir combination treatment beyond the standard care in hospitalized adults with severe COVID-19 [
 <xref rid="bb0695" ref-type="bibr">139</xref>]. Nonetheless, there are several ongoing clinical trials of COVID-19 and the lopinavir-Ritonavir combination, either alone or together with other drugs. The potential synergetic treatments include the combinations with interferons, guanosine-analog RNA synthesis inhibitors, reverse transcriptase inhibitors, or influenza drugs, such as baloxavir marboxil, oseltamivir, and umifenovir [
 <xref rid="bb0560" ref-type="bibr">112</xref>,
 <xref rid="bb0625" ref-type="bibr">125</xref>,
 <xref rid="bb0700" ref-type="bibr">[140]</xref>, 
 <xref rid="bb0705" ref-type="bibr">[141]</xref>, 
 <xref rid="bb0710" ref-type="bibr">[142]</xref>].
</p>
